# Speaker notes / talking points

[Narrow] 157 trials, 93 late-phase — a narrow field.
[One axis] The pipeline walks one type-2 circuit: IL-13, IL-5, Siglec-8, TSLP.
[Established] Steroids, PPIs, diet, dupilumab anchor care.
[Signal] Benralizumab clears eosinophils without full symptom benefit.
[Genetics] Risk loci point upstream, at susceptibility rather than effectors.
[Prevention] The atopic march is interceptable before EoE.
[Diagnostic] One blood draw names the driving food.
[Fit] We occupy two open niches — novel effectors and antigen-specific tolerance.
[Conclusions] We target the cause, not just the downstream cytokine.